Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1960 1
1962 3
1963 4
1964 5
1965 1
1966 1
1967 2
1968 3
1969 1
1970 4
1971 2
1972 5
1973 3
1974 2
1975 4
1976 2
1977 6
1978 6
1979 7
1980 8
1981 11
1982 6
1983 6
1984 6
1985 14
1986 15
1987 20
1988 3
1989 12
1990 9
1991 17
1992 14
1993 21
1994 8
1995 6
1996 12
1997 15
1998 12
1999 25
2000 14
2001 14
2002 31
2003 20
2004 21
2005 31
2006 32
2007 39
2008 45
2009 35
2010 42
2011 51
2012 49
2013 59
2014 56
2015 43
2016 57
2017 56
2018 85
2019 93
2020 61
2021 63
2022 69
2023 8
Text availability
Article attribute
Article type
Publication date

Search Results

1,253 results
Results by year
Filters applied: . Clear all
Page 1
Triggering and resolution of inflammation in NASH.
Schuster S, Cabrera D, Arrese M, Feldstein AE. Schuster S, et al. Nat Rev Gastroenterol Hepatol. 2018 Jun;15(6):349-364. doi: 10.1038/s41575-018-0009-6. Nat Rev Gastroenterol Hepatol. 2018. PMID: 29740166 Review.
An NK-like CAR T cell transition in CAR T cell dysfunction.
Good CR, Aznar MA, Kuramitsu S, Samareh P, Agarwal S, Donahue G, Ishiyama K, Wellhausen N, Rennels AK, Ma Y, Tian L, Guedan S, Alexander KA, Zhang Z, Rommel PC, Singh N, Glastad KM, Richardson MW, Watanabe K, Tanyi JL, O'Hara MH, Ruella M, Lacey SF, Moon EK, Schuster SJ, Albelda SM, Lanier LL, Young RM, Berger SL, June CH. Good CR, et al. Among authors: schuster sj. Cell. 2021 Dec 9;184(25):6081-6100.e26. doi: 10.1016/j.cell.2021.11.016. Epub 2021 Dec 2. Cell. 2021. PMID: 34861191 Free PMC article.
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak Ö, Salles G, Maziarz RT; JULIET Investigators. Schuster SJ, et al. N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1. N Engl J Med. 2019. PMID: 30501490 Clinical Trial.
Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials.
Westin JR, Kersten MJ, Salles G, Abramson JS, Schuster SJ, Locke FL, Andreadis C. Westin JR, et al. Among authors: schuster sj. Am J Hematol. 2021 Oct 1;96(10):1295-1312. doi: 10.1002/ajh.26301. Epub 2021 Aug 13. Am J Hematol. 2021. PMID: 34310745 Free PMC article. Review.
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, Kato K, Sureda A, Greil R, Thieblemont C, Morschhauser F, Janz M, Flinn I, Rabitsch W, Kwong YL, Kersten MJ, Minnema MC, Holte H, Chan EHL, Martinez-Lopez J, Müller AMS, Maziarz RT, McGuirk JP, Bachy E, Le Gouill S, Dreyling M, Harigae H, Bond D, Andreadis C, McSweeney P, Kharfan-Dabaja M, Newsome S, Degtyarev E, Awasthi R, Del Corral C, Andreola G, Masood A, Schuster SJ, Jäger U, Borchmann P, Westin JR. Bishop MR, et al. Among authors: schuster sj. N Engl J Med. 2022 Feb 17;386(7):629-639. doi: 10.1056/NEJMoa2116596. Epub 2021 Dec 14. N Engl J Med. 2022. PMID: 34904798 Clinical Trial.
Mass spectrometry-based metabolomics: a guide for annotation, quantification and best reporting practices.
Alseekh S, Aharoni A, Brotman Y, Contrepois K, D'Auria J, Ewald J, C Ewald J, Fraser PD, Giavalisco P, Hall RD, Heinemann M, Link H, Luo J, Neumann S, Nielsen J, Perez de Souza L, Saito K, Sauer U, Schroeder FC, Schuster S, Siuzdak G, Skirycz A, Sumner LW, Snyder MP, Tang H, Tohge T, Wang Y, Wen W, Wu S, Xu G, Zamboni N, Fernie AR. Alseekh S, et al. Among authors: schuster s. Nat Methods. 2021 Jul;18(7):747-756. doi: 10.1038/s41592-021-01197-1. Epub 2021 Jul 8. Nat Methods. 2021. PMID: 34239102 Free PMC article. Review.
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.
Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, Kato K, Harigae H, Kersten MJ, Andreadis C, Riedell PA, Ho PJ, Pérez-Simón JA, Chen AI, Nastoupil LJ, von Tresckow B, Ferreri AJM, Teshima T, Patten PEM, McGuirk JP, Petzer AL, Offner F, Viardot A, Zinzani PL, Malladi R, Zia A, Awasthi R, Masood A, Anak O, Schuster SJ, Thieblemont C. Fowler NH, et al. Among authors: schuster sj. Nat Med. 2022 Feb;28(2):325-332. doi: 10.1038/s41591-021-01622-0. Epub 2021 Dec 17. Nat Med. 2022. PMID: 34921238 Clinical Trial.
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.
Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, Matasar MJ, Bosch F, Kim WS, Nastoupil LJ, Flinn IW, Shadman M, Diefenbach C, O'Hear C, Huang H, Kwan A, Li CC, Piccione EC, Wei MC, Yin S, Bartlett NL. Budde LE, et al. Among authors: schuster sj. J Clin Oncol. 2022 Feb 10;40(5):481-491. doi: 10.1200/JCO.21.00931. Epub 2021 Dec 16. J Clin Oncol. 2022. PMID: 34914545 Clinical Trial.
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, Fakhri B, Eyre TA, Lamanna N, Patel MR, Alencar A, Lech-Maranda E, Wierda WG, Coombs CC, Gerson JN, Ghia P, Le Gouill S, Lewis DJ, Sundaram S, Cohen JB, Flinn IW, Tam CS, Barve MA, Kuss B, Taylor J, Abdel-Wahab O, Schuster SJ, Palomba ML, Lewis KL, Roeker LE, Davids MS, Tan XN, Fenske TS, Wallin J, Tsai DE, Ku NC, Zhu E, Chen J, Yin M, Nair B, Ebata K, Marella N, Brown JR, Wang M. Mato AR, et al. Among authors: schuster sj. Lancet. 2021 Mar 6;397(10277):892-901. doi: 10.1016/S0140-6736(21)00224-5. Lancet. 2021. PMID: 33676628 Clinical Trial.
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy.
Smith M, Dai A, Ghilardi G, Amelsberg KV, Devlin SM, Pajarillo R, Slingerland JB, Beghi S, Herrera PS, Giardina P, Clurman A, Dwomoh E, Armijo G, Gomes ALC, Littmann ER, Schluter J, Fontana E, Taur Y, Park JH, Palomba ML, Halton E, Ruiz J, Jain T, Pennisi M, Afuye AO, Perales MA, Freyer CW, Garfall A, Gier S, Nasta S, Landsburg D, Gerson J, Svoboda J, Cross J, Chong EA, Giralt S, Gill SI, Riviere I, Porter DL, Schuster SJ, Sadelain M, Frey N, Brentjens RJ, June CH, Pamer EG, Peled JU, Facciabene A, van den Brink MRM, Ruella M. Smith M, et al. Among authors: schuster sj. Nat Med. 2022 Apr;28(4):713-723. doi: 10.1038/s41591-022-01702-9. Epub 2022 Mar 14. Nat Med. 2022. PMID: 35288695 Free PMC article.
1,253 results